Effects of Spirulina platensis supplementation on lipid profile in HIV–infected antiretroviral naïve patients in Yaounde - Cameroon: a randomized trial study by Marthe-Elise Ngo-Matip et al.
Ngo-Matip et al. Lipids in Health and Disease 2014, 13:191
http://www.lipidworld.com/content/13/1/191RESEARCH Open AccessEffects of Spirulina platensis supplementation on
lipid profile in HIV–infected antiretroviral naïve
patients in Yaounde - Cameroon: a randomized
trial study
Marthe-Elise Ngo-Matip1*, Constant Anatole Pieme2, Marcel Azabji-Kenfack2, Prosper Cabral Nya Biapa3,
Nkenfack Germaine3, Englert Heike4, Bruno Moukette Moukette2, Korosky Emmanuel5, Stefanini Philippe6,
Carl Moses Mbofung1 and Jeanne Yonkeu Ngogang2Abstract
Background: Cardiovascular diseases (CVD) and metabolic alterations are among the majors public health concern
that have been reported in people living with HIV infections. Factors contributing to cardio metabolic syndrome in
HIV include body fat distribution, dyslipidemia, insulin resistance, cardiovascular dysfunction and inflammation. The
aim of the study was to determine the effect of Spirulina platensis (Cyanobacteriaceae) supplementation versus local
diet on lipid profile in HIV-infected antiretroviral-naive patients.
Methods: A prospective single-blind, randomized, multicentre study was conducted from February 2010 to December
2012. A total of 320 HIV antiretroviral-naïve patients were screened and 169 were recruited in this study. Patients were
randomized and received either Spirulina supplementation combined with local diet (n = 82) or local diet only (n = 87).
Age, weight, body mass index (BMI), lipid profile, CD4 count, and local food intake variables were assessed on three
separate occasions (three, six and twelve months).
Results: An average age of the patients was 35.6 ± 9 years. The majority of participants were female 67.1%. Regarding
the lipid profile, there is a significant increase in HDL-cholesterol and a significant decrease in total cholesterol,
LDL-cholesterol and triglycerides in the group of patients who consumed Spirulina platensis. A change in the
atherogenic index defined by the ratio CT/HDL-C substitutable by LDL-C/HDL-C and the TC/HDL decreased
significantly from 10.83 at baseline to 2.22 after 12 months (p = 0.21 and p <0.0001) in the patients taking
Spirulina.
Conclusions: Nutritional supplementation with Spirulina combined with a quantitative and qualitative
balanced diet for at least six months can retard an exposition to lipid abnormalities in HIV–infected
antiretroviral-naive patients. Further studies are recommended on a large group of people not infected with
HIV and exposed to cardiovascular risk factors.
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Patients with human immunodeficiency virus (HIV) infec-
tion are at increased risk of developing coronary heart dis-
ease (CHD) although traditional risk factors contribute to
elevate the risk [1]. There is growing evidence that HIV-
infected individual develop more risk of coronary heart
disease (CHD) than healthy patient. Studies showed that
the incidence of the CHD risk of HIV-infected patient
varied from different countries [2]. Recent reports have
shown that cardiovascular deaths accounted for 6.5%
of total deaths in a large observational cohort of
HIV-infected patients from Europe and North America,
for 8% of deaths among HIV-infected people in France,
and for 15% of deaths in a North American HIV out-
patient study [3-6]. In Sub-Saharan Africa, one of the sev-
eral Public Health problems is HIV/AIDS [7]. Since the
early days of the HIV epidemic, the effects of HIV disease
on serum lipids have been described [8]. Cardiovascular
diseases have been the leading cause of morbidity and
mortality in the general population [3] and have now also
been identified as a major cause of death in people with
HIV/AID [9].
Cardiovascular diseases (CVD) have emerged as a
major public health problem and impose an escalating
burden on the health care system in Cameroon. A study
in this country between 1992 and 1997 ranked coronary
artery disease eighth among the CVDs registered with a
prevalence of 1.53 percent [10,11]. A study conducted be-
tween November 2009 and November 2011, in a popula-
tion of 8,389 adults and 706 children consulted in the St.
Elizabeth Catholic General Hospital of Shisong, Cameroon
showed the increase of incidence with 41.5% diagnosed
for Hypertension; 29.6% for congestive heart failure,
12.2% for arrhythmia [12]. Data from the same study
demonstrated and confirmed previous works which showed
that cardiac involvements in human immunodeficiency
virus (HIV) infection, with cor pulmonale and pericarditis
contribute to over 20% of cases of heart failure [12,13].
In Cameroon, about 5.5% of the population are infected
of HIV mostly women and individuals aged between
15 and 49 years are most commonly identified [14].
Studies reported an increase of triglycerides (TG), total
cholesterol (TC), low density lipoprotein cholesterol
(LDL-C), and decrease of high density lipoprotein choles-
terol (HDL-C) has raised concern about increased risk
of atherogenesis and atherosclerotic vascular disease
[15-18]. These abnormalities are common in adults in-
fected with the Human Immunodeficiency Virus (HIV)
[19]. The HIV infection itself has been shown to cause
changes in glucose and lipid metabololism [20,21]. Few
studies have been carried out in Cameroon on distur-
bances in lipid metabolism and nutritional deficiency in
HIV-infected patients [22]. In spite of the relatively
high prevalence of HIV in this country, little is knownabout cardiovascular disease (CVD) among HIV-infected
antiretroviral naive persons [8]. There are numerous evi-
dences that nutritional deficiency (ND) is highly prevalent
in HIV-infected patients, especially among patients from
Sub Saharan Africa [23]. The risk factors of Nutritional
Deficiency in HIV infected patients are: a precarious so-
cial situation, poor adherence to diet modification and
comorbidities. Very few researches on the effects of diet-
ary supplements combined with an appropriate balance
diet and medical follow up of HIV infected patients have
been published. The dietary supplements strategy could
be in the long period slow down the progression of
metabolic complications among HIV-infected anti-
retroviral naïve patients. Due to the difficulties to ac-
cess to a balanced diet, a supplementation of a safety
cyanobacterium such as S. platensis in the diet or in the
treatment of HIV patients naives or under antiretroviral
drugs is necessary [24]. This blue green alga is used
as a food supplement all over the world [25,26]. Stud-
ies have demonstrated its beneficial effects on human
health on glucose, lipid metabolism and blood pres-
sure through its full content in antioxidant combined
with vitamin A, B12, E, proteins and mineral salt and also
in building immunity of patients with HIV infection and
multiple cardiovascular risk factors [24,27-29]. It also
was reported that the protein C-phycocyanin present
in S. platentis play a crucial role in the decrease of hyper-
cholesterolemic action [30,31].
The determination of lipid parameters is not required
during follow-up of HIV-infected patients. Although dis-
turbances in lipid metabolism have been found in HIV-
infected patients, no study has yet been carried out to
determine whether these disturbances are caused by the
treatment or by other factors. However, a previous study
in Cameroon has shown its interest in severely infected
people living with HIV [24].
The present study was designed to assess the potential
effect of S. platensis supplementation on the progression
of atherogenetic dyslipidaemia among HIV-Infected anti-
retroviral naïve patients.
Methods
Nutritional composition of S. platensis
Dry S. platensis powder was obtained from a local farm
of spirulina in Central Africa. It was kindly donated by a
Cameroonian Association of Knowledge-Attitudes-Practices
“KAP” in Yaounde-Cameroon. The Table 1 shows it’s the
composition (g per 100 grams of powder). The total protein
was determined by using the Kjeldahl method [32]. The
total lipids, dietary fiber and ash were determined using
the standard methods of AFNOR [33]. The total sugar
was determined by using standard methods of Cerning
and Guilbot [34] while the minerals salt were described by
using the AOAC [32].
Table 1 Composition of freeze-dried powder of Spirulina
platensis intake in our study
Composition g/100 of dry mass (%) Energetic values
(kilo calories)
Macronutrients:
Total Proteins (g) 61.81 258.36
Lipids (g) 16.06 144.54
Carbohydrates (g) 12.36 51.66
AHK (g) 9.77
Dry mass 88.75









The analysis of the freeze-dried spirulina powder sample obtained from the
Institute of Medical and Medicinal Plants (IMMP) (Yaounde-Cameroon).
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We carried out a longitudinal study in a randomized co-
hort from January 2011 to February 2012. Patients aged
between 18 – 65 years, HIV–infected antiretroviral naïve
to treatment and with CD4 count ≥400 cells/μL were eli-
gible. Patients who shown their CD4 drop to ≤400 cells/μL
during the follow-up were excluded. Participants were also
required not to be on lipid modifying therapies at their en-
rolment. Informed consent was obtained from every sub-
ject prior to the participation. The study was approved by
the Cameroon National Ethic Committee under the fol-
lowing reference number: 123/CNE/SE/2011, Cameroon.
The subjects were recruited by the medical file of the Day
Care Clinic of Central Hospital of Yaounde (CHY) and of
the Biyem-Assi District Hospital. Investigation and inter-
vention were carried out at the Etoug-Ebe Health Center.
Selection, randomization, treatment allocation and follow up
Selected participants (169 subjects) were included in the
study among 116 women and 53 men. Of the 169 sub-
jects, we allocated 87 subjects to the control group (first
group) and 82 subjects to the intervention group (sec-
ond group). HIV infected patients were selected after
checking patients files for CD4 counts above 400 cells/μl
who were ARV naïve to treatment (Figure 1). The two
groups were well matched with respect to age, sex, and
CD4 cells counts. At the entrance of the study, patients
had been fasting for at least eight hours overnight.
The patients of the first group were advised to take a
fresh local balance diet while patients of the secondgroup were asked to add S. platensis in their local diet
during the first six months. The S. platensis was given in
package of powder doses of 10 grams per day. The next
six months were for the follow-up without S. platensis
powder. Anthropometric measurements (weight, height,
BMI) were done at baseline, after six and twelve months
for the two groups.
All anthropometric measurements were done with the
same electronic weighing device (SECA QUALITY SEAL –
GERMANY). The BMI was calculated using Quetelet’s
formula; Weight/height2 and expressed as Kg/m2 to the
nearest one decimal place.
Subjects were treated “as usual” “usual care” treatment
in Cameroon means patients are subjected to practi-
tioner’s choice of therapy. This consists of routine fasting
blood sugar level and lipid profile control after six months.
To monitor these parameters, two types of standardized
questionnaire for demographic characteristics, clinical,
quality of live (alcohol consumption, tabac, physical activ-
ities and dietary habits), and a three day diet intake data
was filled by the subjects at the baseline, during and at the
end of the trial.
Dietary records
Food intake was recorded using a predesigned “three
days” questionnaire. Subjects had to document time,
quantity and quality of food or beverage consumed. They
were instructed to: (1) document all consumed foods and
beverages in as much detail as possible, (2) to weigh foods
(or to estimate doses, if weighing was not possible in some
situations), (3) to document food or beverage intake im-
mediately after consumption and (4) not to change usual
eating habits. Data analysis was performed using the nutri-
tion software EBISpro2011, version 8.0 for Windows. In
analyzing the eating records, nutrients were studied in re-
lation to the dietary reference intakes (DRI) (EBISpro
2011) [35]. The DRI utilized corresponds to the age group
and sex. The nutrients evaluated in this study include are
posted in Table 2. Deficiency was defined as a concentra-
tion below the reference interval: Proteins 57.1 g, Iron 10
mg, Zinc 10 mg, Calcium 1000 mg, Potassium 3500 mg,
Magnesium 350 mg, Cholesterol 300 mg.
Determination of biochemical parameters
The blood samples were obtained through patients in two
tubes of 4 mL, one dry and the content Ethylene diamino
Tetracetic Acid (EDTA). The dry tube was used to deter-
mine the lipid profil using coloring method with Kits
(Human). The LDLC-C levels were determined using
method of Friedewald et al. [36]. The following defini-
tions were used for dyslipidemia: Total cholesterol ≥ 240
mg/dl, Low-density lipoprotein cholesterol ≥ 130 mg/dl,
Triglycerides ≥150 mg/dl, and High-density lipoprotein
cholesterol < 40 mg/dl. TC/HDL-C and LDLC/HDLC
Figure 1 Flow chart describing progress of participants through the Spirulina platensis supplementation trial.
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When the ratio TC/HDL-C > 4.85 and LDL-C/HDLC >
3.55 than the atherogenic index is statistically significant.
Fasting blood sugars were determined using « ULTRA
ONE TOUCH” glucometer. The level of glycemia higher
than ≥ 110 mg/dL were identified like cardiovascular risk
factors.
The Flow Cytometry (FACS CALIBUR II Machine) was
used for the determination of CD4 lymphocytes count in
all patients. Values were expressed as cells/μL.
Statistical analysis
Each experiment was carried out in triplicate. Results were
considered significant at p-value less than 0.05. Data are
presented as mean ± standard deviation or as percentage.Chi-square was performed to determine the significance
of differences in the prevalence of dyslipidemia in both
groups. Student’s t-test version 3.3.2 was used to compare
the lipid parameters of both groups. The statistical SPSS
program (version 16.0) was used for all the analysis.
Results
Dietary records
The results of the nutrients intake of the population the
two groups can be classified in two groups which include
macronutrients and mineral (Table 2). The results showed
the increase of protein intake and the decrease of the
cholesterol level with significant difference during the last
6 months of the study to the group of population who add
S. platensis to their local diet. In contrary to this group,
Table 2 Micronutrients intake of the HIV-ARV naïve population before and after spirulina supplementation
Variables Ctrol/Spi Period Patients received local balance diet Patients received spirulina combined
with a local balance diet
p-value
Proteins (g) 87/82 T0 60.51 ± 16.39 48.03 ± 8.85 <0.001
79/80 T6 62.61 ± 14.12 66.03 ± 9.3 0.10
66/79 T12 60.28 ± 13.52 72.77 ± 7.3 <0.001
Iron (mg) 87/82 T0 12.03 ± 1.12 12.85 ± 2.64 <0.01
79/80 T6 11.86 ± 1.30 16.04 ± 1.20 <0.001
66/79 T12 11.80 ± 1.14 14.67 ± 3.75 <0.001
Zinc (mg) 87/82 T0 81 ± 6.35 70 ± 4.50 <0.001
79/80 T6 6.36 ± 2.67 5.79 ± 1.70 0.15
66/79 T12 4.28 ± 3.16 6.92 ± 1.53 <0.001
Calcium mg 87/82 T0 487.09 ± 194.58 666.18 ± 680.75 <0.02
80/79 T6 509.60 ± 248.11 1339.90 ± 303.37 <0.001
79/66 T12 510.87 ± 220.48 943.85 ± 308.39 <0.001
Potassium (mg) 87/82 T0 1148,48 ± 2,00 766,57 ± 2,40 <0.01
79/80 T6 2306 ± 733.53 4555 ± 798.93 <0.001
66/79 T12 2593 ± 112.44 3241 ± 709.83 <0.001
Magnesium (mg) 87/82 T0 223.23 ± 114.60 250.10 ± 91.99 0.11
79/80 T6 231.61 ± 88.78 428.44 ± 78.5 <0.001
66/79 T12 251.21 ± 143.00 288.00 ± 80.70 0.07
Cholesterol (mg) 87/82 T0 379.37 ± 83.24 464.54 ± 160,74 <0.001
79/80 T6 402.77 ± 66.29 216.32 ± 100.50 <0.001
66/79 T12 413.88 ± 56.05 292.67 ± 55.54 <0.001
Mean values ± SD, Ctrl: Control, Spi: Spirulina group T0: initial period, T6: Six months, T12: Twelve months Mean values ± SD. p < 0.01: Significant difference
between the group.
Ngo-Matip et al. Lipids in Health and Disease 2014, 13:191 Page 5 of 10
http://www.lipidworld.com/content/13/1/191we found the increase of cholesterol level to the other
group and the variation of protein (Table 2). Regarding the
micronutrients intake, the Iron, Calcium and Magnesium
increase significantly during the trial in the population
who supplemented S. platensis in their diet (Table 2).
Characteristics of population studied
The sample population of the study at the baseline was
169 (Figure 1). Among them, four subjects (2.36%) from
the intervention group and 23 subjects from the control
group (13.60%) were dropped out of the trial at the end
of twelve intervention months. Six of the 27 subjects in
the control group and two of three subjects in the inter-
vention group were HIV–negative due to the error of
screening test in the laboratory (Figure 1). Seventeen
subjects in the control group and two subjects in the
intervention group were dropped out due to a decrease in
their CD4 cells count. The distribution of the 27 drop-out
according to the cause of drop-out and treatment group is
presented in (Figure 1).
Finally for the 142 subjects (84.01%) who demonstrated
the atherogenic lipid abnormalities in HIV-infected
antiretroviral-naïve patients were used to continue the
study. Demographic characteristics of the 169 HIV–Infected antiretroviral naïve patients are presented in
(Table 3). The results showed that this sample population
was made of women (76.1%) and men (23.9%). The two
groups were similar with respect to age, sex. The mean
age was 35.6 ± 9 years. The value of the BMI decreases
none significantly during the twelve months in both
groups. The results of clinical characteristics of patients in
the spirulina group (Spi) and control show that the pres-
ence of sexual transmitted infections (3%, 16%), malaria
(6%, 13%) and shingles (3%, 7%). As for lifestyle patients
practiced physical activity drank alcohol and tobacco
smoke (Table 3). The fasting blood sugar was decreased in
the group of patients who add 10 g of S. platensis compare
to the other group which in which the variation was no
linear. No significant difference was observed in fasting
blood sugar in both groups at the first 6 six months. At
the end of the study a significant difference was noted in
these two groups (Table 3).
Changes in lipid profile and atherogenic index
To investigate the cardiovascular risk factors of these
groups of population, the lipid profile which include the
TG, TC, HDL-C, LDL-C and the artherogenic index
were determined.
Table 3 Baseline of demographic and clinical characteristics of patients during the trial
Variables Ctrl/Spi Period Patients received local balance diet Patients received spirulina combined
with a local balance diet
p-value
Age (Years) 87/82 T0 35.43 ± 10.04 36.01 ± 9.44 0,58
Sex (%)
Female 87/82 T0 64.5% (56) 69.8% (60) 0.06
Male 35.6% (31) 25.6% (22)
BMI (kg/m2) 87/82 T0 26.02 ± 4.97 25.29 ± 4.54 0.33
79/80 T6 25.18 ± 6.41 25.41 ± 4.98 0.80
66/79 T12 22.18 ± 1.07 23.26 ± 6.53 0.44
Fasting blood sugar (mg/l) 87/82 T0 115 ± 53,70 105.89 ± 25.91 0.159
79/80 T6 105.00 ± 30.76 103.14 ± 15.93 0.65
66/79 T12 113.77 ± 61,85 95.35 ± 9.63 <0,001
Alcohol 14/169 To 11.9% 11.9%
10/156 T6 11.9% 5.6%
7/145 T12 4.4% 4.4%
Smoking 5/169 To 3% 4.5%
5/169 T6 3% 4.5%
6/169 T12 1.4% 3%
Ctrl: Control, Spi: Spirulina group, T0: initial period, T6: Six months, T12: Twelve months, p< 0.01: Significant difference between the group.
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and LDL-C significantly decreased in the Spi group while
those of the control group increased (Table 4). This result
shows that the consumption of S. platensis positively and
significantly affects the lipids profile. The Figures 2, 3, 4, 5
and 6 show the variation of lipids profile during the
experiment. This results showed that the levels of TG of
patient from Spi group, initially higher than those of
control group significantly dropped at the end of the
intervention (206.89 versus 117.59 p < 0.0001) and (98.90
versus 162.25 p < 0.0001) (Figure 2). In the same popula-
tion, the levels of HDL-C increased significantly from
48.00 to 100.98 p = 0.71, p < 001, p < 0.0001) during the
same period of study (Figure 4). The results of atherogenic
index defined by the ratio of TC/HDL-C or LDL-C/HDL-C
showed these ratio significantly decreased from 10.83 to
2.22 after twelve month (p = 0.21, p = 0.64, p < 0.0001) for
(TC/HDL-C) and from 8.24 to 0.96 (p = 0.26, p = 0.21,
p < 0.0001) (LDL-C/HDL-C) for patients using S. platen-
sis as supplement while for the control group these the
value this ratio increased (Figure 6). These results demon-
strated that the supplementation of S. platensis on diet
have benefit effect on the lipid profile of HIV patients.
Discussion
The present randomized control study was designed to
compare the effects of consumption of S. platensis on some
metabolic parameters among HIV–infected antiretroviral
naïve patients. Studies showed that dietary supplements
are often used by people living with HIV infection [37].Previous research also demonstrated similar use, such as a
study of HIV positive men that found 69% used comple-
mentary medicine products and practices, the most com-
mon of which were dietary supplements [38]. The most
common dietary supplements in people living with HIV/
AIDS (PLWH) are used to ‘boost immune functioning’
such as mega-dose vitamins, and anti-oxidants and body
cleansing products such as teas and herbs to remove
‘toxins’ [39]. It is important to note that while some diet-
ary supplements can adversely interact with prescription
medications [40], some supplements may also have posi-
tive impacts on HIV disease processes. The supplementa-
tion of S. platensis in diet improves the living conditions
of HIV patients by providing macronutrients and en-
ergy which play an important role on the health of these
patients.
The variation of the lipid profile among HIV-infected
antiretroviral naïve patients was determined in the study.
Dyslipidemia is one of the significant modifiable risk fac-
tors for cardiovascular diseases. The dyslipidemia is char-
acterized by a decrease of the levels of high-density
lipoproteins cholesterol (HDL-C), an increase of the levels
of low-density lipoprotein cholesterol (LDL-C) and ele-
vated levels of triglycerides (TG). In the initial state, our
study showed that the level of TC, LDL-C and TG was
lower in the control compare to compare to the group of
patients supplementing with S. platensis. Our observations
are in agreement with previous studies in United States
and other parts of sub-Saharan Africa that documented the
lipid profile of the treatment-naïve HIV-infected individuals
Table 4 Change in lipid profile during the six months of intervention and the follow up in each group
Variables Ctrl/Spi Period Patients received local balance diet Patients received spirulina combined
with a local balance diet
P-value
Total cholesterol (mg/dL) 87/82 T0 194.8 ± 80.1 228.7 ± 96.8 0.17
79/80 T6 216.8 ± 109.4 143.3 ± 45.4 <0.001
66/79 T12 234.9 ± 101.8 141.4 ± 40.1 <0001
HDL cholesterol (mg/dL) 87/82 T0 53.6 ± 18.4 48.0 ± 21.1 0.71
79/80 T6 49.9 ± 21.6 83.2 ± 39.7 <0. 001
88/79 T12 57.3 ± 27.0 100.9 ± 28.7 <0.001
LDL cholesterol (mg/dL) 87/82 T0 120.12 ± 75.8 127.0 ± 92.2 0.60
79/80 T6 138.3 ± 105.8 44.5 ± 33.0 <0.001
66/79 T12 146.3 ± 97.8 29.3 ± 16.8 <0.001
Triglycerides (mg/dL) 87/82 T0 117.6 ± 76.8 206.9 ± 122.7 <0.0001
79/80 T6 150.4 ± 97.5 139.8 ± 64.2 0.44
66/79 T12 167.1 ± 124.8 123.5 ± 44.6 <0.01
CT/HDL (mg/dL) 87/82 T0 3.6 ± 4.3 4.7 ± 4.6 0.21
79/80 T6 4.34 ± 5.1 1.7 ± 1.1 0.64
66/79 T12 4.1 ± 3.0 1.4 ± 1.4 <0.0001
LDL/HDL (mg/dL) 87/82 T0 2.2 ± 4.1 2.6 ± 4.3 0.26
79/80 T6 2.8 ± 4.89 0.53 ± 0.84 0.21
66/79 T12 2.5 ± 3.6 0.3 ± 0.6 <0.0001
Mean values ± SD.
Ctrl: Control, Spi: Spirulina group; TC: HDL-C and LDL-C: HDL-C ratios were used to calculate the atherogenicity index. TC, total cholesterol; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides, P < 0.01: Significant difference between the group.
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serum were higher in the control group compare to the
group of patients supplementing with S. platensis. At the
same time, the concentration of HDL-C increased during
the same period. The increase of the cholesterol levels, in
particular LDL-C, TG and TC in the control group sug-
gest the disturbance in the lipids metabolism which canFigure 2 Concentration of triglycerides levels of the two groups
of patients during the trial.be attributed to the malnutrition [22]. This result demon-
strated that S. platensis positively and significantly affect
the dyslipidemia through the inversion of lipid profile in
the group receiving S. platensis. The increase TG level in
the serum probably caused by an increase of VLDL levels
has previously been found to be linked to an increase inFigure 3 Concentration of total cholesterol levels of the two
groups during the trial.
Figure 4 Concentration of HDL-Cholesterol levels of the two
groups during the trial.
Figure 6 Concentration of artherogenic index of the patients in
the two groups during the trial.
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significantly lower in patients who received S. platensis
as supplement with a significantly higher concentra-
tion of HDL-C in the same group at the end of the trial.
The elevation of the HDL-C level occurs before hypertri-
glyceridemia, correlates with other findings which demon-
strated that supplementation of diet with S. platensis
decreases LDL-C and increases HDL-C with a probable
beneficial effect [29,30]. Investigations on the effects of
lowering blood cholesterol by S. platensis in rats [45,46]
and in different doses (5- 16% of diet) have been published
[30]. These studies demonstrated that HIV infection in-
duces an increase of the TG, LDL-C, TC level and the re-
ductions of HDL-C in accordance of other studies [47,48].
The observed alteration of cholesterol metabolism in
HIV-infected patients may be explained by lipid per-
oxidation [22,47]. The observed alteration of cholesterolFigure 5 Concentration of LDL cholesterol of the two groups
during the trial.metabolism in HIV–infected patients may be explained by
the increase of lipid peroxidation through stimulating the
production of reactive oxygen species [49]. Other mechan-
ism of lipid disorders in ART-naïve HIV-infected patients
is also thought to be cytokine-mediated [44]. A possible
relationship between lipids profile and immune system
has been noted. Constans et al. [50] reported that HIV in-
fection itself induced a progressive increase in TG and
LDL-C. The mechanism used by S. platensis to reduce the
hypercholesterolemia and lipid disorders have not yet
been elucidated although some authors suggest that the
addition of this alga into the diet diminishes the intestinal
absorption of cholesterol as well as the re-absorption of
bile acids in the ileum [51,52]. Thus, they suggest that
spirulina can be considered a functional food capable of
reducing the levels of cholesterol and consequently pre-
venting atherosclerosis. The antioxidant mechanism of
S. platensis can also be suggested due to the presence of
protein C-phycocyanin, which the structure is closed to that
of bilirubin which plays an important physiological role
against reactive oxygen species [31,53]. This C-phycocyanin
protein inhibits oxidative changes in plasma proteins and
aromatic amino acid residues [53], increases activity of the
enzyme lipoprotein lipase, which is a key enzyme in the
metabolism of triglycerides and lipoproteins [54]. These
results showed that S. platensis demonstrated hyperchol-
esterolemia effects. Although dyslipidemia in HIV-
infected patients is believed to carry a similar risk as in
HIV-negative populations, the consistent findings of low
HDL-C in combination with hypertriglyceridemia can
easily increase the burden of cardiovascular diseases in
HIV-infected patients by unwanted proportions [55]. This
is because hypertriglyceridemia and low HDL-C are rec-
ognized independent risk factors for coronary artery dis-
ease. Our results demonstrated the reduction of TG, TC
and LDL-C to the patient receiving S. platensis. The study
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vascular diseases in HIV patients regarding dyslipidemia.
Limitations of the study
Comprehensive cardiovascular risk factors were assessed
in this study. However, the decreased risk of cardiovas-
cular diseases associated with S. platensis intake is well
known [15], and long term use of first-line HAART may
have an impact on cardiovascular systems, which were
not assessed in this study. Others factors not controlled
in the analysis were the mechanisms of S. platensis on
lipoprotein lipase which may have influenced the de-
creased of triglycerides.
Conclusion
The consumption of balance diet combined with S. pla-
tensis powder has beneficial effects of lipids profile in
the intervention group at the end of the trial. From this,
we can assume that a regular consumption of a balanced
diet could slow down metabolic disorders of lipids and
reinforce the immune defense system in HIV infected
antiretroviral naïve patients.
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